candesartan has been researched along with Uremia in 3 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs." | 9.09 | [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999) |
| "The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs." | 5.09 | [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999) |
| " Candesartan significantly reduced aortic atherosclerosis, prevented the upregulation of the uraemia-induced genes and led to changes predicting greater stability of the plaques, without influencing blood pressure or serum lipids." | 3.77 | Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure. ( Bernardi, S; Candido, R; Carretta, R; Fabris, B; Toffoli, B, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardi, S | 1 |
| Candido, R | 1 |
| Toffoli, B | 1 |
| Carretta, R | 1 |
| Fabris, B | 1 |
| Marson, BP | 1 |
| Poli de Figueiredo, CE | 1 |
| Tanus-Santos, JE | 1 |
| Cice, G | 1 |
| Ferrara, L | 1 |
| Tagliamonte, E | 1 |
| Russo, PE | 1 |
| Di Benedetto, A | 1 |
| Iacono, A | 1 |
1 review available for candesartan and Uremia
| Article | Year |
|---|---|
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Doxycycline; Humans; K | 2012 |
1 trial available for candesartan and Uremia
| Article | Year |
|---|---|
[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
1 other study available for candesartan and Uremia
| Article | Year |
|---|---|
Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzimi | 2011 |